Patent intelligence · US
US 7919594
Human anti-CD100 antibodies
Human anti-CD100 antibodies
Patent details — US 7919594
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 5, 2011
- Expiration
- Mar 31, 2031
- Applicant
- VACCINEX, INC.
- Claims
- 36
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00
Quick answer
US 7919594 (Human anti-CD100 antibodies) is held by VACCINEX, INC.. Status: granted. Granted Apr 5, 2011. Expires Mar 31, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- VACCINEX, INC.
- Grant date
- Expiration
- Claims
- 36
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00, A61P37/06
More from VACCINEX, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12201719
Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy
granted -
US 12070500
Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis
granted -
US 12006364
Anti-CD100 antibodies and methods for using the same
granted -
US 12006365
Human anti-semaphorin 4D antibody
granted -
US 11981730
Anti-CXCL13 antibodies and methods of using the same
granted -
US 11859000
Anti-CCR8 antibodies and uses thereof
granted -
US 11660330
Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy
granted -
US 11597765
Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
granted
Frequently asked questions
What is US patent 7919594?
US 7919594 (Human anti-CD100 antibodies) is held by VACCINEX, INC.. Status: granted. Granted Apr 5, 2011. Expires Mar 31, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7919594?
VACCINEX, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 41 pharmaceutical patents for this assignee.
When does US 7919594 expire?
Our index shows an expiration date of Mar 31, 2031 (5 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.